Evidence map›Paper›PMID 39107765›Full record

ArticleJournal of translational medicine2024

Development and validation of novel interpretable survival prediction models based on drug exposures for severe heart failure during vulnerable period.

Yu Guo, Fang Yu, Fang-Fang Jiang, Sun-Jun Yin, Meng-Han Jiang, Ya-Jia Li, Hai-Ying Yang, Li-Rong Chen, Wen-Ke Cai, Gong-Hao He

Abstract readValidation Study
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yu Guo *Department of Clinical Pharmacy, The 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Fang Yu *Department of Clinical Pharmacy, The 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Fang-Fang Jiang *Department of Clinical Pharmacy, The 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Sun-Jun Yin *Department of Clinical Pharmacy, The 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Meng-Han JiangDepartment of Clinical Pharmacy, The 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Ya-Jia LiDepartment of Clinical Pharmacy, The 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Hai-Ying YangDepartment of Clinical Pharmacy, The 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Li-Rong ChenDepartment of Clinical Pharmacy, The 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China.
Wen-Ke CaiDepartment of Cardiothoracic Surgery, The 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China. caiwenke002@126.com.
Gong-Hao HeDepartment of Clinical Pharmacy, The 920th Hospital of Joint Logistics Support Force, 212 Daguan Rd, Kunming, 650032, China. gonghow@hotmail.com.ORCID 0000-0002-1274-3130

Funding

the 2024 Young and Middle-aged Academic and Technical Leaders Reserve Talent Project of Yunnan Province the 2024 Young and Middle-aged Academic and Technical Leaders Reserve Talent Project of Yunnan Provincethe Applied Basic Research Program Yunnan Province of China (Joint Special Project of Kunming Medical University) 202101AY070001-300the Applied Basic Research Program Yunnan Province of China (Joint Special Project of Kunming Medical University) 202401AY070001-367the National Science Foundation of China 81960664
6 · The paper itself

Abstract

backgroundSevere heart failure (HF) has a higher mortality during vulnerable period while targeted predictive tools, especially based on drug exposures, to accurately assess its prognoses remain largely unexplored. Therefore, this study aimed to utilize drug information as the main predictor to develop and validate survival models for severe HF patients during this period.

methodsWe extracted severe HF patients from the MIMIC-IV database (as training and internal validation cohorts) as well as from the MIMIC-III database and local hospital (as external validation cohorts). Three algorithms, including Cox proportional hazards model (CoxPH), random survival forest (RSF), and deep learning survival prediction (DeepSurv), were applied to incorporate the parameters (partial hospitalization information and exposure durations of drugs) for constructing survival prediction models. The model performance was assessed mainly using area under the receiver operator characteristic curve (AUC), brier score (BS), and decision curve analysis (DCA). The model interpretability was determined by the permutation importance and Shapley additive explanations values.

resultsA total of 11,590 patients were included in this study. Among the 3 models, the CoxPH model ultimately included 10 variables, while RSF and DeepSurv models incorporated 24 variables, respectively. All of the 3 models achieved respectable performance metrics while the DeepSurv model exhibited the highest AUC values and relatively lower BS among these models. The DCA also verified that the DeepSurv model had the best clinical practicality.

conclusionsThe survival prediction tools established in this study can be applied to severe HF patients during vulnerable period by mainly inputting drug treatment duration, thus contributing to optimal clinical decisions prospectively.

Indexed as

Heart FailureProportional Hazards ModelsAgedAlgorithmsArea Under CurveDatabases, FactualDeep LearningFemaleHumansMaleMiddle AgedPrognosisReproducibility of ResultsROC CurveSeverity of Illness IndexSurvival AnalysisCox proportional hazards modelDeepSurvRandom survival forestSevere heart failureSurvival model

Identifiers

PMID39107765
PMCPMC11302109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.